Intensity Therapeutics (INTS)
Develops INT230-6, a tumor-injection treatment candidate for solid cancers.
Something off on this page? Send us feedback.
Develops INT230-6, an investigational tumor-injection formulation intended to destroy solid tumors locally and encourage immune recognition. Future revenue would come from approved product sales or licensing; none is approved, and clinical work and manufacturing are outsourced.
Develops INT230-6, an investigational tumor-injection formulation combining established cytotoxic drugs with the DfuseRx platform's SHAO dispersion enhancer. Intended to destroy an injected solid tumor locally, it is designed to expose tumor-specific antigens and encourage systemic immune recognition. No approved or commercial product is disclosed.
Advances that candidate in randomized studies for soft-tissue sarcoma and presurgical triple-negative breast cancer, after earlier research in refractory and metastatic solid tumors. Clinical development spans the United States, Canada, Europe, Australia, Switzerland, and France.
Operates through a small virtualized organization that outsources clinical work and all manufacturing. The pipeline depends on INT230-6, regulatory approvals, trial funding and execution, and qualified sole suppliers for components and finished product.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | H.C. Wainwright | Target | $5 | $7 | ||
| Aug 11, 2026 | Industrial Alliance Securities | Target | $15 | |||
| Aug 12, 2025 | Brookline Capital | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.5M · Total debt $95.0K · Total assets $11.5M · Shareholders' equity $9.2M
- Revenue
- $0
- Operating income
- −$3.1M
- Net income
- −$3.0M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 5.52% | 180.3K shares | |
| Insiders3 holders · as of Jul 1, 2026 | 3.92% | 127.9K shares | |
| Otherremainder | 90.56% | 2.96M shares |
3.26M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.26M in the company's Sep 3, 2026 report, 2.70M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Lewis H. BenderInsiderdirector, officer: President and CEO | 3.63% | 118,549 | Form 4filed Mar 30, 2026 ↗ |
Kingsbury Capital Investment Advisors LLCInstitution | 1.17% | 38,054 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.80% | 26,019 | 13Fas of Mar 31, 2026 |
Sapient Capital LLCInstitution | 0.80% | 26,006 | 13Fas of Mar 31, 2026 |
Nano Cap New Millennium Growth Fund L PInstitution | 0.77% | 25,000 | 13Fas of Mar 31, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Replimune Group
Closest tumor-injection immunotherapy platform rival.
- Amgen
Approved intralesional oncolytic therapy sets a high bar.
- Novartis (ADR)
Pazopanib is a direct investigator-choice comparator in sarcoma.
- Johnson & Johnson
Trabectedin contests late-line liposarcoma and leiomyosarcoma.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Intensity Therapeutics | $4.05 | −0.49% | $10.8M | — | — | — | — |
| Replimune Group | $15.90 | −0.50% | $1.34B | — | — | — | — |
| Amgen | $445.00 | +0.49% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Johnson & Johnson | $275.01 | −0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Median | 27.5 | 18.9 | 6.3 | +6.6% |